Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Advate · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Advate®/turoctocog alfa | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Advate® | DRUG | Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session |
| turoctocog alfa | DRUG | After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session |
Inclusion Criteria: * Severe haemophilia A (FVIII level less than or equal to 1%) * Treatment history of more than 150 exposure days with recombinant or plasma-derived FVIII replacement products * HIV or HCV negative, or if positive the patient is on a stable antiviral regimen at the time of the en...
Advate is used for congenital bleeding disorder, specifically Haemophilia A. It is being studied in a clinical trial for this condition. The drug is currently in Phase 1 development and is being investigated for its safety and action in the body.
Advate is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the stock exchange under the ticker symbol NVO. The company is conducting clinical research on this drug for the treatment of congenital bleeding disorder.
Advate is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied for its safety and pharmacological action in patients with Haemophilia A.
Advate is being studied in clinical trial NCT00837356, titled "Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects." This Phase 1 trial has been completed and enrolled 23 male participants aged 12 years and older.
Advate is not the same as N8. The clinical trial NCT00837356 compares the action and safety of N8 and Advate in Haemophilia A subjects. These are two distinct drugs being evaluated against each other in the study.